Edition:
United States

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

1.88USD
3:59pm EST
Change (% chg)

$-0.01 (-0.53%)
Prev Close
$1.89
Open
$1.89
Day's High
$1.95
Day's Low
$1.85
Volume
76,466
Avg. Vol
128,036
52-wk High
$7.94
52-wk Low
$1.15

Latest Key Developments (Source: Significant Developments)

Conatus Pharmaceuticals Qtrly Loss Per Share $0.15
Wednesday, 1 Aug 2018 04:05pm EDT 

Aug 1 (Reuters) - Conatus Pharmaceuticals Inc ::CONATUS PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROGRAM UPDATES.Q2 REVENUE $8.8 MILLION VERSUS I/B/E/S VIEW $9.1 MILLION.QTRLY LOSS PER SHARE $0.15.  Full Article

Conatus Pharmaceuticals Announces Top-Line Results From Phase 2B POLT-HCV SVR Clinical Trial
Wednesday, 4 Apr 2018 04:05pm EDT 

April 4 (Reuters) - Conatus Pharmaceuticals Inc ::CONATUS PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM PHASE 2B POLT-HCV SVR CLINICAL TRIAL.THE TRIAL DID NOT MEET ITS PRIMARY ENDPOINT IN HETEROGENEOUS OVERALL TRIAL POPULATION.BASED PROOF OF CONCEPT IN LIVER FIBROSIS AND CIRRHOSIS SUPPORTS FURTHER EVALUATION.CONATUS PHARMACEUTICALS INC - ENCORE-NF FOR NASH FIBROSIS TOP-LINE RESULTS EXPECTED IN FIRST HALF OF 2019.CONATUS PHARMACEUTICALS INC - ENCORE-LF FOR LIVER FUNCTION WITH TOP-LINE RESULTS EXPECTED IN SECOND HALF OF 2019.  Full Article

Conatus Pharmaceuticals reports Q3 revenue of $9.6 million
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Conatus Pharmaceuticals Inc :Conatus Pharmaceuticals Inc reports third quarter 2017 financial results and program updates.Q3 revenue $9.6 million.Q3 revenue view $16.1 million -- Thomson Reuters I/B/E/S.Conatus Pharmaceuticals Inc - qtrly ‍net loss per share $0.13.  Full Article

EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC
Wednesday, 18 Oct 2017 04:05pm EDT 

Oct 19 (Reuters) - Conatus Pharmaceuticals Inc :EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC.Conatus Pharmaceuticals - ‍continue to evaluate potential internal, external opportunities with goal of announcing initial pipeline expansion plans later in 2017​.  Full Article

BRIEF-Conatus Completes Enrollment In Phase 2B Clinical Trial Of Emricasan In Patients With Decompensated Nash Cirrhosis

* CONATUS ANNOUNCES COMPLETION OF ENROLLMENT IN ENCORE-LF PHASE 2B CLINICAL TRIAL OF EMRICASAN IN PATIENTS WITH DECOMPENSATED NASH CIRRHOSIS